Education
About Us
Working with TipRanks
Follow Us
Sandoz Group Ltd Sponsored ADR (SDZNY)
OTHER OTC:SDZNY
SDZNY Stock Chart & Stats
$71.74
$0.55(1.34%)
At close: 4:00 PM EST
$71.74
$0.55(1.34%)
Day’s Range― - ―
52-Week Range$36.26 - $71.74
Previous CloseN/A
Volume11.52K
Average Volume (3M)1.03K
Market Cap
$30.48B
Enterprise Value$28.08B
Total Cash (Recent Filing)$1.39B
Total Debt (Recent Filing)$5.69B
Price to Earnings (P/E)130.0
Beta0.36
Next Earnings
Mar 18, 2026EPS EstimateN/A
Last Dividend Ex-Date
Apr 22, 2025Dividend Yield1.01%
Share Statistics
EPS (TTM)0.88
Shares Outstanding440,000,000
10 Day Avg. Volume0
30 Day Avg. Volume1,031
Financial Highlights & Ratios
PEG Ratio-174.11
Price to Book (P/B)2.13
Price to Sales (P/S)1.68
P/FCF Ratio290.18
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit6.65
Enterprise Value/Ebitda33.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sandoz Group Ltd Sponsored ADR News
SDZNY FAQ
What was Sandoz Group Ltd Sponsored ADR’s price range in the past 12 months?
Sandoz Group Ltd Sponsored ADR lowest stock price was $36.26 and its highest was $71.74 in the past 12 months.
What is Sandoz Group Ltd Sponsored ADR’s market cap?
Sandoz Group Ltd Sponsored ADR’s market cap is $30.48B.
When is Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date?
Sandoz Group Ltd Sponsored ADR’s upcoming earnings report date is Mar 18, 2026 which is in 100 days.
How were Sandoz Group Ltd Sponsored ADR’s earnings last quarter?
Sandoz Group Ltd Sponsored ADR released its earnings results on Aug 07, 2025. The company reported $0.882 earnings per share for the quarter, beating the consensus estimate of N/A by $0.882.
Is Sandoz Group Ltd Sponsored ADR overvalued?
According to Wall Street analysts Sandoz Group Ltd Sponsored ADR’s price is currently Overvalued.
Does Sandoz Group Ltd Sponsored ADR pay dividends?
Sandoz Group Ltd Sponsored ADR pays a Annually dividend of $0.727 which represents an annual dividend yield of 1.01%. See more information on Sandoz Group Ltd Sponsored ADR dividends here
What is Sandoz Group Ltd Sponsored ADR’s EPS estimate?
Sandoz Group Ltd Sponsored ADR’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sandoz Group Ltd Sponsored ADR have?
Sandoz Group Ltd Sponsored ADR has 440,000,000 shares outstanding.
What happened to Sandoz Group Ltd Sponsored ADR’s price movement after its last earnings report?
Sandoz Group Ltd Sponsored ADR reported an EPS of $0.882 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 11.603%.
Which hedge fund is a major shareholder of Sandoz Group Ltd Sponsored ADR?
Currently, no hedge funds are holding shares in SDZNY
Sandoz Group Ltd Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Decreased
By 55.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.07%
12-Months-Change
Fundamentals
Return on Equity
2.68%
Trailing 12-Months
Asset Growth
11.86%
Trailing 12-Months
Company Description
Sandoz Group Ltd Sponsored ADR
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
SDZNY Company Deck
SDZNY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted a strong first half performance driven by strategic launches and financial improvements. However, there are challenges related to price erosion and costs associated with separation. The sentiment is balanced with growth opportunities and market challenges.View all SDZNY earnings summariesTechnical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Takeda Pharmaceutical Company
―
Ownership Overview
―
Insiders
0.19% Mutual Funds
0.05% Other Institutional Investors
99.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---